Anti-CCL3 / MIP-1 alpha antibody [EPR16618-90],Abcam,AB179638

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse

Application

Flow Cyt (Intra), IP, ICC/IF, sELISA, WB, EIA

Platform ID

BAB930721299

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-CCL3 / MIP-1 alpha antibody [EPR16618-90]
Cat. No.AB179638
HostRabbit
IsotypeIgG
ReactivityMouse
ApplicationFlow Cyt (Intra), IP, ICC/IF, sELISA, WB, EIA
ClonalityMonoclonal
Clone NumberEPR16618-90
Concentration0.622 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). See full target information Ccl3

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.